Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) insider Jo Ann Beltramello sold 13,356 shares of Momenta Pharmaceuticals stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $30.03, for a total value of $401,080.68. Following the transaction, the insider now owns 70,522 shares in the company, valued at approximately $2,117,775.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Jo Ann Beltramello also recently made the following trade(s):
- On Friday, February 7th, Jo Ann Beltramello sold 2,691 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $31.06, for a total transaction of $83,582.46.
- On Friday, January 24th, Jo Ann Beltramello sold 1,219 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $28.19, for a total transaction of $34,363.61.
- On Tuesday, January 14th, Jo Ann Beltramello sold 122,589 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $23.42, for a total transaction of $2,871,034.38.
NASDAQ MNTA opened at $31.88 on Friday. The company has a market cap of $3.16 billion, a P/E ratio of -14.69 and a beta of 2.01. The stock has a 50-day moving average of $26.17 and a two-hundred day moving average of $17.38. Momenta Pharmaceuticals, Inc. has a 1-year low of $9.51 and a 1-year high of $32.37.
Several analysts recently issued reports on the stock. Wells Fargo & Co assumed coverage on shares of Momenta Pharmaceuticals in a report on Wednesday, November 6th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. upgraded shares of Momenta Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $14.00 to $30.00 in a report on Tuesday, January 14th. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, December 11th. SunTrust Banks boosted their price objective on shares of Momenta Pharmaceuticals to and gave the company a “buy” rating in a report on Wednesday, January 15th. Finally, ValuEngine lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, December 24th. Four investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $31.79.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Recommended Story: Most Volatile Stocks – What Investors Need to Know to Maximize ROI
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.